NCT03168035View on ClinicalTrials.gov

Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Advanced CancerLymphoma
Interventions
DRUG

NC-4016

"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

NanoCarrier Co., Ltd.

INDUSTRY

NCT03168035 - Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter